The reported statements, read against the company's own industry.
Financials view
Market Capitalization
410.89BCNY
61.63B · vs all stocks (USD)
Updated Oct 24, 2026
Trailing P/E
92.30x
vs Biotechnology peers
Updated Oct 24, 2026
Revenue (TTM)
40.90BCNY
6.13B · vs all stocks (USD)
Updated Oct 24, 2026
Profit Margin
10.70%
vs Biotechnology peers
Updated Oct 24, 2026
Beta
0.6090x
vs all stocks
Updated Oct 24, 2026
52-Week Change
-3.61%
vs all stocks
Updated Oct 24, 2026
Market Capitalization
410.89BCNY
61.63B · vs all stocks (USD)
Updated Oct 24, 2026
Enterprise Value
2.72TCNY
407.99B · vs all stocks (USD)
Updated Oct 24, 2026
Trailing P/E
92.30x
vs Biotechnology peers
Updated Oct 24, 2026
Forward P/E
50.90x
vs Biotechnology peers
Updated Oct 24, 2026
PEG Ratio
0.7179x
Updated Oct 24, 2026
Price to Sales (TTM)
67.04x
vs Biotechnology peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 10.05×.Updated Oct 24, 2026
Price to Book (MRQ)
11.81x
vs Biotechnology peers
Updated Oct 24, 2026
Enterprise to Revenue
66.50x
vs Biotechnology peers
Updated Oct 24, 2026
Gross Margin
89.76%
vs Biotechnology peers
Updated Oct 24, 2026
Profit Margin
10.70%
vs Biotechnology peers
Updated Oct 24, 2026
Operating Margin
19.06%
vs Biotechnology peers
Updated Oct 24, 2026
Return on Assets (TTM)
7.46%
vs Biotechnology peers
Updated Oct 24, 2026
Return on Equity (TTM)
14.66%
vs Biotechnology peers
Updated Oct 24, 2026
Revenue (TTM)
40.90BCNY
6.13B · vs all stocks (USD)
Updated Oct 24, 2026
Revenue per Share (TTM)
55.27CNYUpdated Oct 24, 2026
Quarterly Revenue Growth
29.60%
vs Biotechnology peers
Updated Oct 24, 2026
Gross Profit (TTM)
36.36BCNY
5.45B · vs all stocks (USD)
Updated Oct 24, 2026
EBITDA (TTM)
1.18BCNY
176.28M · vs all stocks (USD)
Updated Oct 24, 2026
Net Income (TTM)
4.38BCNY
656.33M · vs all stocks (USD)
Updated Oct 24, 2026
Quarterly Earnings Growth (YoY)
151.30%
vs Biotechnology peers
Updated Oct 24, 2026
Operating Cash Flow (TTM)
9.90BCNY
1.49B · vs all stocks (USD)
Updated Oct 24, 2026
Levered Free Cash Flow (TTM)
5.87BCNY
879.86M · vs all stocks (USD)
Updated Oct 24, 2026
Payout Ratio
0.00%
vs Biotechnology peers
Updated Oct 24, 2026
Revenue
5.34BUSDFY2025 · Dec 31, 2025
Cost of Goods Sold
668.54MUSDFY2025 · Dec 31, 2025
Gross Profit
4.67BUSDFY2025 · Dec 31, 2025
Operating Income
447.14MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
416.85MUSDFY2025 · Dec 31, 2025
Income Tax Expense
129.92MUSDFY2025 · Dec 31, 2025
Net Income
286.93MUSDFY2025 · Dec 31, 2025
EBIT
475.09MUSDFY2025 · Dec 31, 2025
EBITDA (Income Statement)
616.77MUSDFY2025 · Dec 31, 2025
Research & Development
2.15BUSDFY2025 · Dec 31, 2025
Selling, General & Administrative
2.08BUSDFY2025 · Dec 31, 2025
Non-operating Interest Income
70.50MUSDFY2025 · Dec 31, 2025
Non-operating Interest Expense
58.23MUSDFY2025 · Dec 31, 2025
EPS (Basic)
0.2000USDFY2025 · Dec 31, 2025
EPS (Diluted)
0.1900USDFY2025 · Dec 31, 2025
Basic Shares Outstanding
1.42BSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
1.42BSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
286.93MUSDFY2025 · Dec 31, 2025
Operating Cash Flow
739.60MUSDFY2025 · Dec 31, 2025
Free Cash Flow
553.76MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
4.61BUSDFY2025 · Dec 31, 2025
Interest Paid
52.45MUSDFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
286.93MUSDFY2025 · Dec 31, 2025
Depreciation & Amortization
141.69MUSDFY2025 · Dec 31, 2025
Deferred Taxes (CF)
9.47MUSDFY2025 · Dec 31, 2025
Stock-based Compensation
510.86MUSDFY2025 · Dec 31, 2025
Other Non-cash Items
-88.48MUSDFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-164.95MUSDFY2025 · Dec 31, 2025
Change in Accounts Payable (CF)
79.83MUSDFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-35.74MUSDFY2025 · Dec 31, 2025
Capital Expenditures
-185.84MUSDFY2025 · Dec 31, 2025
Net Intangibles (CF)
-80.69MUSDFY2025 · Dec 31, 2025
Purchase of Investments
-11.83MUSDFY2025 · Dec 31, 2025
Sale of Investments
3.45MUSDFY2025 · Dec 31, 2025
Other Investing Activity
-1.24MUSDFY2025 · Dec 31, 2025
Net Investing Cash Flow
-195.46MUSDFY2025 · Dec 31, 2025
Long-term Debt Issuance
850.59MUSDFY2025 · Dec 31, 2025
Long-term Debt Payments
-1.08BUSDFY2025 · Dec 31, 2025
Net Short-term Debt Issuance
-811.11MUSDFY2025 · Dec 31, 2025
Other Financing Charges
859.37MUSDFY2025 · Dec 31, 2025
Net Financing Cash Flow
-181.61MUSDFY2025 · Dec 31, 2025
Shares Outstanding
1.47BSharesUpdated Oct 24, 2026
Float Shares
1.05BSharesUpdated Oct 24, 2026
% Held by Insiders
2.58%
vs all stocks
Updated Oct 24, 2026
% Held by Institutions
28.22%
vs all stocks
Updated Oct 24, 2026
Total Cash (MRQ)
34.02BCNY
5.10B · vs all stocks (USD)
Updated Oct 24, 2026
Total Cash per Share (MRQ)
3.45CNYUpdated Oct 24, 2026
Total Debt (MRQ)
13.68BCNY
2.05B · vs all stocks (USD)
Updated Oct 24, 2026
Total Debt to Equity (MRQ)
0.3961x
vs Biotechnology peers
Updated Oct 24, 2026
Current Ratio (MRQ)
3.40x
vs Biotechnology peers
Updated Oct 24, 2026
Book Value per Share (MRQ)
23.52CNYUpdated Oct 24, 2026
Total Assets
8.19BUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
6.23BUSDFY2025 · Dec 31, 2025
Total Liabilities
3.83BUSDFY2025 · Dec 31, 2025
Total Non-current Assets
1.95BUSDFY2025 · Dec 31, 2025
Total Non-current Liabilities
2.00BUSDFY2025 · Dec 31, 2025
Total Current Liabilities
1.83BUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents
4.55BUSDFY2025 · Dec 31, 2025
Accounts Receivable
865.08MUSDFY2025 · Dec 31, 2025
Inventory
608.23MUSDFY2025 · Dec 31, 2025
Accounts Payable
479.04MUSDFY2025 · Dec 31, 2025
Short-term Debt
77.99MUSDFY2025 · Dec 31, 2025
Other Current Liabilities
121.06MUSDFY2025 · Dec 31, 2025
Long-term Debt
1.01BUSDFY2025 · Dec 31, 2025
Other Non-current Liabilities
879.77MUSDFY2025 · Dec 31, 2025
Common Stock (Book)
144.00KUSDFY2025 · Dec 31, 2025
Retained Earnings
-8.32BUSDFY2025 · Dec 31, 2025
Total Shareholders' Equity
4.36BUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
205.51CNYUpdated Oct 24, 2026
52-Week High
319.24CNYUpdated Oct 24, 2026
52-Week Change
-3.61%
vs all stocks
Updated Oct 24, 2026
Beta
0.6090x
vs all stocks
Updated Oct 24, 2026
50-Day MA
264.96CNYUpdated Oct 24, 2026
200-Day MA
256.68CNYUpdated Oct 24, 2026
Avg 10-Day Volume
3.31MSharesUpdated Oct 24, 2026
Avg 30-Day Volume
2.99MSharesUpdated Oct 24, 2026
Diluted EPS (TTM)
3.01CNYUpdated Oct 24, 2026
Other Income / Expense
-42.55MUSDFY2025 · Dec 31, 2025
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Revenue has grown steadily, and the cash arriving matches reported profit.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 9.72: safe zoneNotable
Altman Z-Score: 9.72
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $61.63B, higher than 95% of all stocks globallySignificant
Market cap (USD): 61,625,754,545.062Global P95: 25,915,547,689.943
Revenue is $6.13B, above the global median of $566.17MNotable